產(chǎn)品目錄

規(guī)格	1 mg 5 mg 10 mg
CAS	4431-01-0
別名
化學(xué)名	(3Z)-3-butylidene-4,5-dihydro-2-benzofuran-1-one
分子式	C12H14O2
分子量	190.23
溶解度	≥ 16.45mg/mL in DMSO
儲存條件	-20°C,
General tips	For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping Condition	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request

產(chǎn)品描述：

IC50: 2.27 and 4.78 μM against L1210 and K562 cell lines

Z-Ligustilide, isolated and purified from the essential oil of A. sinensis. Z-Ligustilide has been reported to facilitate blood circulation and attenuate inflammatory pain behavior.

In vitro: Previous results showed pretreatment with Z-Ligustilide (LIG) improved cell viability significantly. The apoptosis rate in glutamate-induced PC12 cells decreased in the presence of LIG. Western blot results indicated that LIG could decrease the release of Cyt C from mitochondria, up-regulate Bcl-2/Bax ratio and down-regulate Caspase-3 protein expression, resulting in protecting PC12 cells from apoptosis [1].

In vivo: In ovariectomized (OVX) osteopenic rats, the anti-inflammatory potential of LIG was determined by ELISA. LIG was found to be able to inhibit OVX-induced up-regulation of NF-κB activation and the production of TNF-α, iNOS, IL-1β, ICAM-1 and COX-2 significantly. In addition, LIG could suppress MDA and PMN infiltration. The significant anti-inflammatory effect of Z-Ligustilide in experimental OVX osteopenic rats clearly demonstrated that there might be an inflammatory component in the etiology of osteoporosis [2].

Clinical trial: N/A

特別提醒：

1. 本產(chǎn)品僅供科研使用。請勿用于醫(yī)藥、臨床診斷或治療，食品及化妝品等用途。請勿存放于普通住宅區(qū)。

2. 為了您的安全和健康，請穿好實驗服并佩戴一次性手套和口罩操作。

原創(chuàng)作者：上海莼試生物技術(shù)有限公司

在線咨詢

留言注意事項：

1.遵守中華人民共和國有關(guān)法律、法規(guī)，尊重網(wǎng)上道德，承擔一切因您的行為而直接或間接引起的法律責任。

2.請您真實的反映產(chǎn)品的情況,不要捏造、誣蔑、造謠。如對產(chǎn)品有任何疑問,也可以留言咨詢。

3.未經(jīng)本站同意，任何人不得利用本留言簿發(fā)布個人或團體的具有廣告性質(zhì)的信息或類似言論。

您感興趣的產(chǎn)品*
您的單位*
聯(lián)系人*
聯(lián)系電話*
詳細地址*
常用郵箱*
請輸入您對我們的意見或建議*
驗證碼*